Video Latest - ecancer

PD-1 therapy with eribulin for triple negative MBC

Dr Sara Tolaney - Dana–Farber Cancer Institute, Boston, USA

9 Dec 2016

ASH 2016: Multiple myeloma highlights

Prof Marivi Mateos, Prof Philippe Moreau, Prof Saad Usmani, Prof Heinz Ludwig

6 Dec 2016

DVd vs Vd for relapsed or refractory myeloma: CASTOR trial update

Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain

$DVd vs Vd for relapsed or refractory myeloma: CASTOR trial update ( Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain )$

6 Dec 2016

ASH 2016 highlights: breaking new ground in haematology

Dr Giovanni Martinelli - Università di Bologna, Bologna, Italy

6 Dec 2016

Azacitidine plus nivolumab against acute myeloid leukaemia

Prof Naval Daver - MD Anderson Cancer Center, Houston, USA

6 Dec 2016

ALL: Combining paediatric-type therapy with minimal residual disease

Dr Alessandro Rambaldi - Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

5 Dec 2016

ASH 2016: AML, CLL and leukaemogenesis latest

Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA

5 Dec 2016

Advances in CLL from ASH 2016

Prof Stephan Stilgenbauer, Prof Clemens-Martin Wendtner, Prof Steven Coutre And Dr Jeffery Jones

5 Dec 2016

Obinutuzumab extends PFS for follicular lymphoma in GALLIUM trial

Dr Andrew Davies - University of Southampton, Southampton, UK

4 Dec 2016

Ibrutinib in CLL: RESONATE and resistance

Dr Jennifer Woyach - The Ohio State University Medical Center, Columbus, USA

4 Dec 2016

Novel antibody boosts responses in newly diagnosed AML

Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA

3 Dec 2016

Vadastuximab talirine in combination for newly diagnosed AML

Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA

3 Dec 2016

Video